Gilead’s Lenacapavir Access Strategy in R...

By João L. Carapinha

October 14, 2024

Gilead Sciences, Inc. has announced important initiatives to increase access to lenacapavir, a potentially transformative HIV medication

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.